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Recent efforts toward HIV vaccine development
include the design of immunogens that can engage
B cell receptors with the potential to affinity mature
into broadly neutralizing antibodies (bnAbs). V2-
apex bnAbs, which bind a protein-glycan region on
HIV envelope glycoprotein (Env) trimer, are among
the most broad and potent described. We show
here that a rare ‘‘glycan hole’’ at the V2 apex is en-
riched in HIV isolates neutralized by inferred precur-
sors of prototype V2-apex bnAbs. To investigate
whether this feature could focus neutralizing re-
sponses onto the apex bnAb region, we immunized
wild-type rabbits with soluble trimers adapted from
these Envs. Potent autologous tier 2 neutralizing
responses targeting basic residues in strand C of
the V2 region, which forms the core epitope for V2-
apex bnAbs, were observed. Neutralizing mono-
clonal antibodies (mAbs) derived from these animals
display features promising for subsequent broad-
ening of the response.
INTRODUCTION
Neutralizing antibodies to HIV can protect against immunodefi-
ciency viruses in animal models (Moldt et al., 2012; Pegu et al.,
2014; Shingai et al., 2014), and their induction is seen as impor-
tant for the generation of a successful HIV vaccine (Burton and
Hangartner, 2016; Haynes and Mascola, 2017). The HIV enve-
lope glycoprotein (Env) controls virus entry into target cells and
is the sole target for neutralizing antibodies (nAbs) that block
this process. Env is a membrane-anchored trimer of hetero-
dimers (gp120-gp41)3 that conceals much of its surface from222 Cell Reports 21, 222–235, October 3, 2017 ª 2017 The Author(s)
This is an open access article under the CC BY license (http://creativeantibody recognition using a shield of N-linked glycans (Behrens
et al., 2016; Bonomelli et al., 2011; Lee et al., 2016; Stewart-
Jones et al., 2016; Ward andWilson, 2017). The antibody-acces-
sible protein surfaces are highly variable in sequence and
dynamic due to shifting N-linked glycan sequons, resulting in
neutralizing responses that are mostly isolate specific (Moore
et al., 2012; Sok et al., 2014). Despite these viral evasion strate-
gies, broadly neutralizing antibodies (bnAbs) can emerge after
years of affinity maturation during natural HIV infection in some
individuals. These bnAbs, their affinity maturation from naive
precursors, and their binding to HIV Env are being intensively
studied in the hope that the information gathered can be used
to design immunogens to elicit bnAbs, a process that has been
termed ‘‘reverse vaccinology 2.0’’ (Burton, 2002, 2017; Rappuoli
et al., 2016).
Several epitope regions on Env have been identified as tar-
gets for bnAbs (McCoy and Burton, 2017; Ward and Wilson,
2017; West et al., 2014). One such region is the trimer apex,
comprising overlapping quaternary epitopes formed by the var-
iable loop (V2) and N160 glycan from all three gp120 protomers
(V2 apex) (Julien et al., 2013; McLellan et al., 2011; Pancera
et al., 2013; Walker et al., 2009). In studies involving large co-
horts of infected donors, bnAbs directed to the V2 apex emerge
relatively frequently (21%–42% of all bnAbs) and early in infec-
tion, making the V2 apex region an attractive target for immu-
nogen design (Georgiev et al., 2013; Landais et al., 2016;
Walker et al., 2010). There are currently four prototype
V2-apex bnAbs, and each was derived from different HIV-in-
fected donors (PG9, CH01, PGT145, and CAP256.09) (Bon-
signori et al., 2011; Doria-Rose et al., 2014; Walker et al.,
2009, 2011). All four prototypes bind to a core epitope involving
a lysine-rich b strand ‘‘C’’ (basic patch) in the V2 domain (HXB2
168–171) and N-linked glycans, particularly at residue 160
(N160) and, to a somewhat lesser extent, residue 156 (N156)
(Andrabi et al., 2015; Gorman et al., 2016; McLellan et al.,
2011; Pancera et al., 2013). The structural feature that allows.
commons.org/licenses/by/4.0/).
(legend on next page)
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antibody penetration through the glycan shield to contact the
V2 basic patch is an unusually long heavy-chain complemen-
tarity-determining region 3 (CDRH3) loop, which for PG9 and
CAP256.09 makes contact with strand-C lysines through a
conserved germline-encoded tripeptide YYD motif originating
from the same D-gene (Andrabi et al., 2015; McLellan et al.,
2011; Pancera et al., 2013).
We and others have previously described viruses that are
neutralized by inferred precursors (iPs) of prototype apex
bnAbs (Andrabi et al., 2015; Gorman et al., 2016). It is logical
that the Env immunogens derived from these viruses might
effectively expand V2-apex bnAb precursor lineages in hu-
mans. We showed that one of these Env sequences could
be adapted to produce recombinant soluble near-native
SOSIP.664 trimers (referred to hereafter as SOSIPs). Here, we
describe the identification of a larger panel of four SOSIPs
derived from V2-apex bnAb iP-sensitive viruses, which have
antibody-binding profiles representative of functional Env
spikes. Sequence analysis revealed that three of these Envs
lack predicted N-linked glycosylation (PNG) sites at position
130 (HXB2 numbering) and within the V2 hypervariable region
(designated the V20, HXB2 position 183–191) that constitute a
rare ‘‘glycan hole’’ at the V2 apex, as has been described at
other Env locations (Crooks et al., 2015; Klasse et al., 2016;
McCoy et al., 2016). Incorporation of PNG sites to fill this hole
disrupted neutralization by iP antibodies, suggesting this
glycan hole may aid the elicitation of bnAbs to this general
region.
To assess the ability of our immunogens to focus responses
to the V2 apex region, we immunized rabbits using all four V2-
apex bnAb iP-binding SOSIPs given individually, as a mixture,
or sequentially. Marked differences were found among the tri-
mers in their ability to elicit autologous nAbs. The dominant
target of these responses was the same glycan hole at the V2
apex that was required for neutralization by the iP versions of
prototype V2-apex bnAbs. One trimer immunogen consistently
elicited responses involving strand-C basic patch residues,
which are also key contacts for prototype bnAbs. Therefore, it
appears that this hole in the glycan shield may indeed improve
exposure of the V2-apex bnAb region to neutralizing re-
sponses. Encouragingly, we also report the elicitation of
neutralizing responses targeting several heterologous tier 2 vi-
ruses in one animal that was immunized with a SOSIP trimer
cocktail.Figure 1. Sensitivity of Select Envs to iP Versions of V2-Apex Prototyp
(A) Env iP neutralization table. HIV isolates neutralized by three prototype V2-ape
pseudovirus are in micrograms per milliliter. Envelope features, including the stra
presence of PNG sites at specific sequences are marked by a plus (+) sign (two
NXT/S sequons are indicated by a bold red N in sequence alignments. Envs that
(B) Trimer V2-apex model. The BG505 trimer (PDB: 5T3X) highlighting residue 13
variation in this region between select Envs is shown in the insert on the right. Re
187; HXB2) are highlighted in yellowwith NXS/T sequons underlined. 130 and V20 s
strand-C basic residues N156 and N160 (pink).
(C) iP antibody neutralization of V2-apex glycan variants. Shown are neutraliza
antibodies against virus variants with V2-apex PNG sites at 130 or within the V20
(D) Biolayer interferometry (BLI) showing the binding and dissociation curves for
was measured by incubation with the indicated concentrations of SOSIP (180–30
from the IgG in PBS buffer was further recorded.
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Glycan Holes Are aMajor Determinant for V2-Apex bnAb
iP Binding on Select Env-Based Trimers
HIV isolates screened for sensitivity to neutralization by iP ver-
sions of PG9, CH01, and PGT145 antibodies (Andrabi et al.,
2015; Gorman et al., 2016) and the CAP256 unmutated common
ancestor sequence (UCA) (Doria-Rose et al., 2014) are shown in
Figure 1A. We compared Env sequences from eight iP-sensitive
isolates to identify critical features that might facilitate neutraliza-
tion. Strikingly, four of these Envs lacked PNG sites at locations
in close proximity to key bnAb contacts, the strand-C lysines,
suggesting the presence of a glycan hole at the V2 apex.
These Envs are derived from C108.c03 (hereafter referred to as
C108, clade AE), CRF-T250 (hereafter CRF250, clade AG),
WITO4160.33 (hereafter WITO, clade B), and Q23.env17
(clade A), all neutralized by both PG9 and CH01 iP antibodies
(Figure 1A).
The V2-apex glycan hole is modeled onto the BG505 SOSIP
structure (Gristick et al., 2016), in Figure 1B to reveal absent
PNG sites at position 130 (HXB2 numbering) and within a loop
projecting apically from the V2 hypervariable region designated
V20 (HXB2 183–191). This loop is unstructured in the BG505
model (HXB2 185–187). The glycan at 130 (N130) is conserved
in 56% of viruses from a 120-virus panel (Seaman et al., 2010)
representing the global diversity of HIV. However, at least one
PNG site is highly conserved in the V20 loop (94% of viruses in
the panel), so that viruses lacking glycans at both sites represent
only 4% of these isolates. To directly investigate the role of
these glycans on V2-apex iP antibody binding, we incorporated
PNG sites at N130 and/or within the V20 region in three of these
Envs and assessed their neutralizing sensitivity to the iPs. PNG
sites added to at least one of these two positions either reduced
or eliminated neutralizing activity of the iPs, with the effect being
more prominent for N130 (Figure 1C). For BG505 (already lacking
a PNG site at 130), the removal of two PNG sites within the V20
region rendered this virus sensitive to neutralization by the
CH01 iP (Figure 1C). HIV-001428, the only other virus from the
120-virus global panel lacking glycans at both these positions,
was not neutralized by any iP (Figure 1A), suggesting that the
absence of glycans at both 130 andwithin the V20 is not sufficient
for iP reactivity in some Env contexts. HIV-001428 has an espe-
cially long V20 region (Figure 1B). This may obstruct iP access to
important strand-C contacts. iP antibodies can tolerate glycanse bnAbs
x bnAb iP Abs and the CAP256 UCA. Neutralization IC50 values against each
nd-C lysine-rich basic patch sequence and V1 V2 regions, are also noted. The
glycans are ++) and the total number of PNG sites in the V1V2 loop are given.
were successfully generated as soluble native trimers are in blue font.
0 (blue spheres) and the base of the V20 hypervariable region loop. Sequence
sidues between the last structured amino acids in the V20 region loop (185 and
ites lie close to each other and to the V2-apex bnAb core epitope, including the
tion IC50 values (in micrograms per milliliter) for mature or iP PG9 and CH01
region either added or removed.
PG9 and CH01 iPs and for CAP256 UCA to PGT145-purified SOSIPs. Binding
0 s) measured in delta (nanometers) or response units. Dissociation of SOSIP
at either or both of these positions in some Env sequence
contexts, such as MGRM8, MGRM14, ZM233, and 16055 (Fig-
ure 1A). V1 or V2 lengths did not correlate with iP sensitivities
(Figure 1A).
To investigate whether the iP-sensitive Envs could be used as
immunogens to guide a V2-apex-specific neutralizing response,
we first incorporated SOSIP.664-trimer-stabilizing modifications
as previously described (Pugach et al., 2015; Sanders et al.,
2013). Four of these Envs (CRF250, C108, WITO, and MGRM-
002-8 [hereafter MGRM8]) (Figure S1A) produced soluble trimer
when purified by PGT145 antibody (Ab) affinity chromatography.
PGT145 enriches only native-like homogeneous trimer popula-
tions that are properly folded (Pugach et al., 2015). All SOSIP
trimers eluted as single peaks with sizes consistent with
the trimeric form by size exclusion chromatography (SEC)
(Figure S1B).
Next, we assessed the binding of the PG9, CH01 iPs, and
CAP256 UCA Abs to the soluble SOSIP trimers by biolayer inter-
ferometry (BLI). Consistent with the neutralization data, the iP
Abs displayed significant binding to the soluble trimers (Fig-
ure 1D). Among the four SOSIPs, only the CRF250 trimer showed
binding to all three iP Abs. The virus encoding this Env shares V2-
apex sequence similarity with CAP256 superinfecting virus
(CAP256.SU), a descendant of which likely triggered the
CAP256 V2-apex bnAb lineage (Bhiman et al., 2015; Doria-
Rose et al., 2014). CRF250 also has a pattern of neutralization
sensitivity similar to CAP256.SU by the CAP256 bnAbs. While
WITO was neutralized by both PG9 and CH01 iPs, binding of
its SOSIP could only be detected for CH01, possibly reflecting
subtle differences between the Env as a membrane-associated
functional trimer on the viral surface and the PGT145-enriched
SOSIP-stabilized recombinant trimers. In all, we demonstrate
that a glycan hole at the V2 apex is associated with binding to
iP versions of V2-apex bnAbs in three of four vulnerable HIV-1
isolates that could be successfully produced as soluble trimers.
These trimers showed iP-binding properties mostly consistent
with iP neutralization data.
The V2-Apex iP-Binding SOSIPs Form Homogeneously
Folded Trimers and Display Native-like Properties
Next, we characterized the SOSIP trimers that bound V2-apex
iPs, biophysically and antigenically, to determine their suitability
as immunogens. PGT145-purified SOSIPs formed well-ordered,
3-fold symmetric trimers by negative-stain electron microscopy
(EM) (Figure 2A), which were efficiently cleaved into gp120 and
gp41 as assessed by SDS-PAGE under reducing conditions
(Figure S1B). Enzymatically released and fluorescently labeled
N-glycans were analyzed by hydrophilic interaction ultraper-
formance liquid chromatography (HILIC-UPLC) (Behrens et al.,
2016; Pritchard et al., 2015) to determine the glycan composition
for each trimer. The profiles were comparable to BG505 SOSIP
expressed in 293T cells, with a large proportion of high-mannose
glycans Man8–9GlcNAc2 (Man8–9) and a smaller fraction of
mannose Man5–7GlcNAc2 (Man5–7) and complex glycans
(Figure 2B).
Differential scanning calorimetry (DSC) was used to assess the
thermal stability of the trimers and showed single unfolding
peaks for CRF250, C108, and MGRM8 trimers with thermaldenaturation midpoints (Tm) of 68.1
, 70.8, and 65.1, respec-
tively. These thermostabilities are similar to that of BG505
SOSIP, which has a Tm of 68.1
C (Sanders et al., 2013). The
WITO SOSIP trimer showed two melting peaks (Tm) at 57.7

and 66.9, indicating the presence of an uncharacterized hetero-
geneous mixture of trimer populations (Figure 2C).
To evaluate the overall antigenic profile of the SOSIP trimers
generated here, we used BLI to characterize the binding of tri-
mers and their sequence-matched gp120 proteins to a panel
of 85 Env-specific neutralizing and non-neutralizing Abs directed
to a range of epitopes. These include antibodies targeting the V2
apex (n = 30), V3-glycan (n = 16), CD4-binding site (CD4bs) (n =
14), gp120-gp41 interface (n = 10), non-neutralizing V3 (n = 11),
and CD4-induced (CD4i) (n = 3) and gp41 cluster-1 (n = 1) (Fig-
ures 2D and S1C). The trimers generally displayed strong reac-
tivity with bnAbs. All four trimers showed robust binding to the
V2-apex-directed and gp120-gp41 interface bnAb epitopes.
Weak or no antibody binding to the corresponding sequence-
matched gp120s was observed, consistent with the trimer-spe-
cific/preferring nature of bnAbs to these sites. V3-glycan bnAbs
were also trimer preferring, with the exception of reactivity with
MGRM8 Env, where they bound to trimer and gp120 equally.
The trimer preference of V3-glycan bnAb PGT121 lineage inter-
mediates has been described previously (Sok et al., 2013).
CD4-binding-site bnAbs did not show a preference for trimers,
and CRF250 showed unusually low antibody binding to this
site. We included four non-neutralizing V2-apex-directed Abs
(2909, C108G, 830A, and 697) to examine whether the glycan
hole exposed non-neutralizing V2 epitopes. Only WITO and
MGRM8 SOSIP trimers weakly bound 830A (Figure S1C). Non-
neutralizing V3 reactivity was seen with all trimers. WITO showed
V3 reactivity similar to that observed for its gp120 monomer.
CRF250 and MGRM8 trimers showed reduced V3 reactivities
compared with their respective gp120s. C108 trimer showed
the lowest reactivity, with only three V3-specific monoclonal an-
tibodies (mAbs) showing binding over 0.2 response units (RUs)
(Figure 2D). However, binding to C108 gp120 was also lower
than for other strains. Trimer V3 reactivities are consistent with
some unfolding or breathing and exposure of V3 in a fraction of
SOSIP molecules, as described for other HIV strains (Sanders
et al., 2013). Additionally, the MGRM8 trimer showed reactivity
with two CD4i mAbs, suggesting that it may be somewhat prone
to partial unfolding or opening to the CD4-bound form (Fig-
ure 2D). We further tested the ability of these mAbs to neutralize
viruses pseudotyped with Envs corresponding to the four SOSIP
timers and observed a strong correlation between binding and
neutralizing activity (Figure 2E). These data suggest that the
four recombinant immunogens are in conformations representa-
tive of their native functional states on viral surfaces.
Immunization of Rabbits with V2-Apex iP-bnAb-Binding
Soluble Trimers Elicits Autologous Neutralizing
Responses to Varying Extents
To evaluate the immunogenicity of the iP-binding trimers and
determine whether they could guide a V2-apex-focused neutral-
izing response, we chose New Zealand white rabbits (Oryctola-
gus cuniculus) as an animal model. This is because rabbits
have previously induced well-characterized high-titer tier 2Cell Reports 21, 222–235, October 3, 2017 225
Figure 2. Biophysical and Antigenic Properties of iP-Binding Soluble Trimers
(A) Negative-stain EM. Class average, negative-stain EM images of CRF250, C108, WITO, and MGRM8 native trimers in descending order.
(B) SOSIP glycan composition. Elution time of enzymatically released N-glycans from SOSIP immunogens in HILIC-UPLC. Area of eluted peaks represents the
quantity of a particular glycoform (indicated above the peak). Pie diagrams indicate glycoform ratios for each of the immunogens.
(C) Differential scanning calorimetry (DSC) showing the thermal stability of the SOSIP immunogens and their sequence-matched gp120s. Protein denaturation is
measured in kilocal/mol/C. Melting peak temperature (Tm) is indicated above the peak.
(D) mAb binding to SOSIPs. Maximal binding in response units (RUs) of 500 nM CRF250 (red), C108 (blue), WITO (orange), and MGRM8 (purple) SOSIPs (colored
circles) as well as their sequence-matched gp120s (black circles) to a panel of 85 mAbs measured by BLI. The Abs are divided by epitope as indicated on the far
left y axis. RU values are given in Figure S1C.
(E) Neutralization activities. Pseudovirus neutralization IC50 values plotted against SOSIP-binding response units show a strong correlation (two-tailed
Spearman R).
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Figure 3. Rabbit Trimer Immunizations and Elicited Neutralizing Responses
(A) Immunization schedule. Six groups of 4 female NewZealandwhite rabbitswere immunizedwithmixtures or individual SOSIPs as indicatedby the colored circles.
50 mg total protein and 100 U Iscomatrix were given intramuscularly (IM) at 0, 1, 3, and 6 months. Serum or plasma was collected at times indicated by red arrows.
(legend continued on next page)
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neutralization in response to other SOSIP immunogens (Klasse
et al., 2016; Sanders et al., 2015). Further, rabbit and human rep-
ertoires share similar CDRH3 length frequencies and amino acid
compositions (Lavinder et al., 2014), and this region is thought to
be critical for V2-apex bnAb function.
Groups of four, 3-month-old, female rabbits were immunized
with the individual SOSIP trimers, a cocktail of all four trimers,
or with each trimer sequentially as depicted in Figure 3A. Each
immunization contained 50 mg trimer given with 100 U Iscomatrix
adjuvant injected intra-muscularly (IM). Animals were immunized
at 0, 4, and 12 weeks. A final boost, unique to each group, was
administered at 24 weeks post-prime. For this final boost,
groups immunized with individual SOSIP trimers were given a
cocktail of the three other heterologous trimers used in the study
(total protein in the cocktail remained at 50 mg/dose); the cock-
tail-immunized group received a final injection of all four SOSIPs,
and the sequentially immunized group received its final SOSIP
trimer (Figure 3A). The sequential immunization protocol relied
on the conserved gp41 sequence to provide adequate helper
T cell epitopes, and SOSIP-binding titers from this group show
prime-boost responses, suggesting that adequate T cell help
was available for B cells responding to the variant immunogens
(Figure S2A). Peripheral blood mononuclear cells (PBMCs) and
sera were collected at the time points indicated in Figure 3A.
Neutralization against the autologous virus was first assessed
using rabbit immune sera (Figure S2B), but to allow quantifica-
tion of the response (in micrograms per milliliter) of immunoglob-
ulin G (IgG), all analyses were subsequently carried out using
polyclonal-protein-A/G-purified IgG from serum.
Autologous neutralization peaked after the second boost as
reported for BG505 SOSIP trimers in rabbits (Figure 3B) (Klasse
et al., 2016; McCoy et al., 2016; Sanders et al., 2015). The indi-
vidual SOSIP trimers appear to differ in their ability to raise autol-
ogous nAbs, although group sizes were small. For instance,
C108 trimer reproducibly elicited strong autologous neutraliza-
tion titers in 4 out of 4 animals, while CRF250, WITO, and
MGRM8 trimers elicited autologous neutralization titers in 3 out
of 4, 1 out of 4, and 0 out of 4 animals, respectively (Figure 3B).
In the SOSIP-mixture-immunized group, two animals devel-
oped autologous neutralizing titers against the C108 virus, and
one of these rabbits (P5672) also developed neutralizing activity
against two other immunogen-matched autologous viruses
(CRF250 and MGRM8) (Figure 3B). Interestingly, this was the
only animal in the study to develop high titers of nAbs to
MGRM8 virus, and animals immunized with MGRM8 alone did
not. In the sequential immunization group, no animal developed
significant neutralizing responses to any of the four immunogens
(Figure 3B).(B) Autologous and tier 1 neutralization responses in immunized rabbits. Serum I
B4C) was assessed for neutralizing ability against the sequence-matched pseud
pseudoviruses (gray boxes) on the left side of the table. Data are arranged by immu
time point in each group is indicated across the top of the table by a colored circle
micrograms per milliliter) of IgG purified from rabbit serum. Samples are indicate
responses are colored.
(C) Neutralization of heterologous viruses by SOSIPmixture immunized rabbit, P56
is shown for five tier 2 clade AE viruses (92TH is an unconfirmed tier 2 virus)
neutralization and SDs from triplicate experiments are given. Orange, blue, and red
IgG with WITO (orange), C108 (blue), or CRF250 SOSIPs, respectively.
228 Cell Reports 21, 222–235, October 3, 2017Tier 1 viruses expose a number of epitopes that are hidden
on tier 2 viruses and can be neutralized by antibodies that
target relatively conserved regions and are therefore cross-reac-
tive but not broadly neutralizing against primary isolates (Sea-
man et al., 2010). Animals in all the immunogen groups
developed robust neutralization titers to tier 1a viruses from
clades B and C, except for the C108-only group (Figure 3B),
but there was no correlation between autologous neutralization
and heterologous tier 1 neutralization (Figure S2C).
Eight Tier 2 Viruses Can Be Neutralized by Responses in
One Animal Immunized with the Trimer Mix
All animals that showed autologous neutralizing activity after the
second boost were screened for neutralizing breadth using a
number of tier 2 pseudoviruses selected based on similarity
with component immunogen Envs (either gp120 or V1 V2
sequence; Figure S3A). Animal P5672 from the cocktail-immuni-
zation group showed neutralizing activity against five heterolo-
gous, tier 2 viruses. These included AC10 (subtype-B),
R2184.c03, BJOX028000, BJOX25000, and 92TH01 (subtype-
AE) viruses (Figure 3C). P5672 neutralization activity against
these isolates could be adsorbed by C108 and CRF250, but
not WITO, SOSIP trimers (Figures 3C and S3A). These isolates
did not lack a common glycan compared with the immunogens
(Figure S3B). To investigate the effect of preexisting immunolog-
ical memory on the elicitation of nAbs, animals originally
exposed to only one of the four immunogens were boosted
with a mix of all three heterologous trimers used in the study.
No high-titer neutralizing responses were elicited to any SOSIPs
in the final boost, suggesting these immunogens do not strongly
recall preexisting potentially cross-reactive neutralizing re-
sponses (Figures 3A and 3B).
Serum-Binding Titers to Env Do Not Predict the
Elicitation of Autologous Neutralizing Responses
Serum-antibody-binding titers to Env preparations were deter-
mined by ELISA. Rabbit IgG purified from serum was used to
generate half maximal effective concentration (EC50) values
given in micrograms per milliliter of polyclonal purified IgG. We
assessed binding to SOSIP trimers, monomeric gp120s, and
V3 peptides (Figure S2A). Similar autologous-binding titers
were elicited by all immunogens used in this study. Titers ap-
peared after the first boost and improved only slightly after the
second boost. This trend was observed in both SOSIP trimer
and gp120 monomer ELISAs. Autologous-binding EC50 values
are outlined by immunogen colored boxes in Figure S2A. There
was no correlation between autologous gp120 or SOSIP trimer
binding titer and autologous nAb responses (Figure S2C). TheregG from rabbit pre-bleeds or at 14 days post-immunization (B1, B2, B3C, and
ovirus for the SOSIP immunogens used in this study (colored boxes) or tier 1
nization group from left to right, and the immunogenmost recently given for the
. Pseudovirus neutralization by rabbit immune serum IgG is given as the IC50 (in
d by rabbit identification numbers to the left of IC50 values. Higher neutralizing
72. Virus neutralization as a function of rabbit immune serum IgG concentration
, neutralized by the cocktail immunized rabbit P5672. The average percent
curves show neutralization of these same viruses after absorption of the P5672
Figure 4. Specificities of Neutralizing Responses
(A and B) Trimer dependence of neutralizing abs for the 10 rabbits with high titer neutralizing responses in this experiment are shown. D368R autologous SOSIP or
gp120 protein was used to adsorb IgG from bleed ‘‘3C’’ samples before neutralization in the TZMB-l assay. The plots in (A) are neutralization data for 9 rabbits that
raised responses to the autologous virus only so the sequence-matched SOSIP or gp120 was used to adsorb IgG in each sample. The plots in (B) are
neutralization data for the three viruses that were neutralized by SOSIP mixture immunized rabbit, P5672, after the second boost. Absorption of neutralization by
WITO, C108, and CRF250-gp120 or SOSIP was assessed for each virus. Error bars represent SD between replicate data points.
(C) Envelope mutants of the viruses neutralized by rabbit immune IgG were generated as indicated in the left-hand column (HXB2 numbering). These include
N160/N156 glycan knockouts, addition of PNG sites at predicted glycan holes, and mutation of the strand-C V2-apex bnAb core epitope of basic residues (169
and 171). In addition, wild-type viruses grown in the presence of kifunensine (Kif) were included. Neutralization IC50s for these different pseudoviruses are given in
mg/ml of rabbit IgG (identification number is given across the top). The limit of detection is 100 mg/mL. Titration curves are shown in Figure S4.
(D) BG505 trimer side view (PDB: 5XT3) showing the glycan hole targeted at 234/276 in some immunized rabbits (comparewith C). Glycans are absent at positions
234 (blue) and 276 (purple) in CRF250 trimer and 234 in MGRM8. resulting in glycan holes.was a difference in the cross-reactivity of antibody responses
generated by the different SOSIP immunogens in gp120 ELISA
(Figure S2A). C108 SOSIP trimer elicited the lowest levels of
antibodies cross-reactive with CRF250, MGRM8 and WITO
gp120s. All immunogens elicited SOSIP cross-reactive anti-
bodies. The immunogens also elicited different levels of autolo-
gous V3 reactivity when assessed for by ELISA using
sequence-matched V3 loop peptides (Figure S2A). C108 elicited
relatively low V3 titers, consistent with its inability to elicit good
tier 1 neutralizing responses or cross-reactive gp120 antibodies,
which suggests that its V3 epitope remains fairly well concealedduring immunization. V3 titers, like tier 1 neutralization, did not
correlate with autologous neutralizing responses overall
(Figure S2C).
Trimer Specificity of nAb Responses
To determine whether the neutralizing responses generated
were SOSIP trimer specific, we carried out IgG adsorption as-
says by pre-incubating IgG purified at the B3C time point with
excess sequence-matched D368R trimer or gp120 protein (Fig-
ure 4A). As expected, sequence-matched SOSIP trimers ad-
sorbed neutralization activity from all samples (Figure 4A). WithCell Reports 21, 222–235, October 3, 2017 229
respect to sequence-matched monomeric gp120 adsorption,
we found that the neutralizing activity was completely adsorbed
from the CRF250-immunized group in all three neutralizing rab-
bits, indicating no trimer-specific neutralizing IgG responses
were elicited. The neutralizing samples from WITO, and 3 of
4 C108 immunized rabbits, showed only partial adsorption by
sequence-matched gp120, suggesting some preference for a
trimeric quaternary epitope. Only one C108-immunized animal
(P3902) showed no adsorption by gp120 and presumed full
dependence on a trimeric quaternary structure for neutralizing
activity (Figure 4A).
We performed SOSIP/gp120 adsorption assays on the serum
IgG from rabbit P5672. Sequence-matched SOSIP trimers ad-
sorbed the C108, CRF250, and MGRM8 neutralizing activities
in this sample as expected, but there was also some cross-strain
adsorption of neutralizing activity. CRF250 completely adsorbed
the neutralizing activity against MGRM8 virus, suggesting the
presence of MGRM8/CRF250 cross-nAbs in this rabbit. None
of the immunogen-matched gp120s adsorbed autologous
neutralization against any virus, suggesting a dependence of
all neutralizing activities on trimeric Env in this rabbit (Figure 4B).
Autologous Neutralizing Responses Predominantly
Focus on the Lysine-Rich Region that Forms the Core
Epitope for V2-Apex bnAbs
We hypothesized that neutralizing responses were targeting
glycan holes on the neutralizing surfaces of the closed trimer im-
munogens, similar to observations with other SOSIP immuno-
gens (Klasse et al., 2016; McCoy et al., 2016). Therefore, we
generated a panel of virus variants in which PNG sites were
added at the positions of the putative glycan holes (Figure S3B).
We then assayed the effects on the neutralizing activity of IgG
samples (Figures 4C and S4A). PNG sites introduced at the V2
apex at residue 130 or within the V20 region (183–191) reduced
the neutralizing activity in seven of the ten neutralizing rabbit
IgG samples. These included the only animal that developed
neutralizing activity against WITO (P4354), four of the six C108
neutralizing responses (P3901, 3902, 3903, and 5670), and two
of the four CRF250 neutralizing responses (3907 and P3898). A
similar sensitivity to filling in the glycan holes is seen for the iP
versions of prototype V2-apex bnAbs (Figure 1A). This result
demonstrates that SOSIP trimers lacking glycans at 130 and
within the V20 region can immunofocus autologous neutralizing
responses onto epitopes overlapping those bound by prototype
bnAb iPs. To further explore the specificity of the predominant
rabbit responses, viruses were made with substitutions in the
strand-C basic lysine patch (K169/K171) and with substitutions
to remove the N160/N156 glycans, all critical for prototype V2-
apex bnAb neutralization (Andrabi et al., 2015). Remarkably, all
four C108-elicited neutralization responses, which mapped to
the V2 apex, also relied on the strand-C basic patch residues
for activity (Figures 4C and S4A). In general, neutralizing re-
sponses were unaffected or improved in virus variants lacking
the N160 or N156 glycans or against viruses grown in the pres-
ence of kifunensine (kif) (Figures 4C and S4A).
A minority of neutralizing responses elicited in this study tar-
geted a second glycan hole common to only the CRF250
(HXB2 234/276) and MGRM8 (HXB2 234) immunogens (Fig-230 Cell Reports 21, 222–235, October 3, 2017ure S3B). These include the CRF250 activity elicited in animal
P3906 and both the CRF250 and MGRM8 responses elicited in
rabbit P5672 immunized using the SOSIP mixture (Figures 4C
and S4A). Overall, the neutralizing responses induced in this
study were directed to both trimer-specific epitopes and those
found on monomeric gp120. The responses predominantly tar-
geted glycan holes around the apex and the lysine residues
that form the core epitope for V2-apex bnAbs.
Neutralizing mAbs Isolated from C108- and CRF250-
Trimer-Immunized Rabbits Partially Recapitulate the
Corresponding Serum Specificity
To further identify and characterize the fine specificities of the
trimer-induced neutralizing responses, we sorted antigen-spe-
cific B cells from PBMCs using immunogen-matched trimer
probes. The heavy-chain (VH) and light-chain (VL) transcripts
from antigen-specific B cells were recovered by single-cell
PCR amplification as previously described (McCoy et al.,
2016). Only six nAbs were identified from hundreds of antigen-
specific B cells derived from all ten neutralizing rabbit PBMC
samples, showing that the overwhelming majority of specific an-
tibodies are directed to non-neutralizing epitopes. The neutral-
izing mAbs include three from one C108-immunized rabbit
(P3903; mAbs 3903-1, 3903-2, and 3903-3) and three from two
CRF250-immunized rabbits (one from P3907 [mAb 3907-1] and
two from P3898 [mAbs 3898-1 and 3898-2]). Antibody germline
V, D, and J genes were assigned using the international immuno-
genetics information system (IMGT) database (Lefranc et al.,
1999) and are shown in Figure 5A. The antibodies had CDRH3s
between 10 and 17 residues in length, while complementarity-
determining region 3 of the light chains (CDRL3s) were between
10 and 15 residues, which is longer than those typically seen in
human antibodies. Most mAbs possessed a YDmotif at the cen-
ter of their CDRL3s (at the V-J gene junction), reminiscent of the
YYD motif in CAP256.09 and PG9 CDRH3s that are associated
with binding to the strand-C basic residues (Figures 5A and
S5A). One mAb (3907-1) had a YDDYmotif centered on the mid-
dle of its 16-amino-acid CDRH3. Two of the three C108 mAbs
from animal P3903 (1 and 2) appear to be members of the
same lineage despite differing assignments of their light chain
(LC) germline V-genes (Figure S5A).
Epitope specificities of the mAbs were mapped in the same
way as the polyclonal rabbit serum responses shown in Fig-
ure 4C. Mostly, mAbs recapitulated the properties of the sera
from the source rabbit, with some variations with regards to
the effect of the Env glycan variants. Activities of all three
C108-specific neutralizing mAbs relied on the strand-C basic
residues K169 and K171, as seen for all V2-apex bnAb proto-
types. PNG sites introduced to fill glycan holes at 130 or within
the V20 region could reduce their activity, and the effect was
strongest for N130, as was observed for iP versions of prototype
human bnAbs (Figures 5B and S4B). The activity of the CRF250-
elicited mAbs also showed sensitivity to the strand-C lysines but
were variably tolerant of glycans at N130 and within the V20 (Fig-
ures 5B and S4B). NomAb could neutralize the heterologous iso-
lates assayed.
Individual mAbs did not necessarily reflect sera in terms of the
effects of kif on virus neutralization. Three mAbs showed
Figure 5. Neutralizing Monoclonal Rabbit Antibodies Derived from Three Different Immunized Animals
(A) Heavy and light (kappa) chains including genetic identity to their most similarO. cuniculus germline genes (from the IMGT database), CDR lengths, and CDR3
sequences. YD motifs in the heavy CDRH3 or kappa CDRL3 loops are highlighted.
(B) Neutralization IC50 values of three C108-specific mAbs (in micrograms per milliliter) are given to the right of values for the parent rabbit immune serum IgG IC50
values for a variety of C108 variants (left column). 3903-1 and 3903-2 are members of a clonal lineage (Figure S5A).
(C) Neutralization IC50 values of CRF250-specific mAbs derived from two different animals. As in (B), parent immune serum IgG IC50 values are given to the left of
the values for the mAbs against the virus variants indicated in the left column.enhanced or unaltered neutralization of virus grown in kif-treated
cells. In contrast, a complete loss of the neutralizing activity was
observed for three other mAbs, a property typical of most V2-
apex bnAb prototypes (Andrabi et al., 2015; Doores and Burton,
2010).
Elimination of N160 and N156 sites had varying effects on
autologous neutralization by mAbs. N160 elimination improved
neutralization activity for all C108-specific mAbs, while elimi-
nating the N156 glycan site rendered C108 virus non-functional,
precluding investigation of neutralization. Elimination of N160
had a minimal effect on CRF250 mAb activity. One CRF250
V2-apex-specific mAb required a glycan at N156 for activity,
and the two others showed reduced neutralization without this
glycan (Figures 5C and S4B), in contrast to the polyclonal
neutralizing response of the source rabbit, which was minimally
affected.
In all, the six V2-apex-reactive neutralizing mAbs isolated in
this study only partially reproduced neutralizing activities present
in the source animals. However, they illustrate that a diversity of
autologous responses to the V2 apex can be elicited, and some
of these recapitulate properties of iP versions of prototype V2-
apex bnAbs, including a requirement for basic residues at 169/
171 and a sensitivity to glycans at 130 and within the V20 region.
Some mAbs also require N160 and/or N156 glycans for
neutralization.
DISCUSSION
HIV vaccine strategies that target specific naive B cells followed
by boosts designed to shepherd primed responses toward
bnAbs have recently attracted much attention (Burton, 2017;
Haynes and Mascola, 2017; Klein et al., 2013; Xiao et al.,2009). For the quaternary V2-apex epitope targets, native Env tri-
mers are likely to be the most appropriate immunogens, and
thus, it is key to identify trimers that bind to naive B cell receptors
(BCRs) that possess the potential to evolve into bnAb lineages.
In vitro binding to iP versions of bnAbs is encouraging, but the
true test of value comes in whether the trimers can elicit the
appropriate antibodies in vivo. Here, we investigated a range
of V2-apex bnAb-iP-binding trimers as immunogens in a rabbit
model.
First, we showed that a glycan hole (Crooks et al., 2015; Klasse
et al., 2016; McCoy et al., 2016) at the trimer apex, resulting from
the absence of PNG sites at positions 130 andwithin the V20, was
strongly associated with binding of iP versions of V2-apex
bnAbs. Subsequently, we showed that SOSIP trimers with this
glycan hole successfully elicited apex-focused neutralizing re-
sponses in rabbits. While induction of V1V2-specific responses
has been reported previously in several species (Liao et al.,
2013; Zolla-Pazner et al., 2016), none described vaccine elicita-
tion of V2-focused neutralizing responses.
The SOSIP immunogens described here differed in their ability
to reproducibly elicit apex-neutralizing responses. Trimers C108,
CRF250, WITO, andMGRM8 elicited neutralization that could be
mapped to the apex in 3 out of 4, 2 out of 4, 1 out of 4, and 0 out of
4 animals, respectively. With a caveat that the group sizes are
small, there are several possible reasons these immunogens
might elicit neutralizing responses to this epitope with differing
consistency: (1) The presence of a glycan hole may be important,
as the only immunogen that failed to elicit V2-apex-directed
neutralizing responses was MGRM8 SOSIP trimer, which has
the least extensive glycan hole. This trimer lacks N130 but it
does possess a PNG site within the V20 region. The V2-apex
glycan hole in C108, CRF250, and WITO immunogens shouldCell Reports 21, 222–235, October 3, 2017 231
be similar in size, as these isolates possess identical PNG sites in
this region of the trimer. Other factors may therefore contribute
to differences in immunogenicity here. (2) Differing immunogen
stability. The most successful trimer, C108, showed the highest
proportion of trimers in a tightly closed native conformation by
negative-stain EM and was the most thermostable. In addition,
this immunogen had the lowest reactivity to non-neutralizing hu-
manmAbs and elicited the lowest levels of tier 1 neutralizing, V3-
binding, and gp120 cross-reactive antibodies in rabbits. These
data suggest that in addition to being a tightly packed trimer
with minimal exposure of non-neutralizing epitopes, this immu-
nogen is stable enough to maintain conformation throughout
the immunization process, potentially contributing to its ability
to focus responses onto neutralizing epitopes like the apex
glycan hole. In general, trimer thermostability was associated
with an improved ability to reproducibly elicit autologous neutral-
ization, as has been demonstrated previously (Feng et al., 2016).
(3) Differing V2-apex iP reactivity. One of the more effective im-
munogens, CRF250, binds all of the PG9, CH01, and CAP256
precursor antibodies, suggesting there are potentially multiple
ways for this trimer specifically to engage V2-apex-directed
naive BCRs and giving it a potential advantage with regard to
nAb elicitation. (4) Differing strand-C basic residue sequences.
The V2-apex strand-C patch (HXB2 168–171) makes essential
contact with prototype V2-apex bnAbs in the form of strong polar
interactions involving basic side chains on Env. Notably, one of
the trimers that induced less reproducible neutralization, WITO,
has an isoleucine residue at the 169 position instead of the
more common lysine, which may negatively impact the ability
to induce appropriate V2-targeted Abs. Indeed, the limited
neutralization coverage of the CAP256 V2-apex bnAbs against
the clade B viruses has been associated with the lack of a posi-
tively charged residue at position 169 (Doria-Rose et al., 2014,
2015). Therefore, the chemical nature of strand-C residues in
the V2-apex prime and boost immunogens may need to be
tightly regulated to favor responses along bnAb developmental
pathways.
In addition to comparing four iP targeting SOSIPs as immu-
nogens individually, 2 out of 4 rabbits immunized with the
SOSIP mixture developed high-titer nAbs to the C108 virus,
and one of these (P5672) neutralized viruses corresponding
to two of the other immunogens (CRF250 and MGRM8). The
mixture was uniquely able to elicit potent neutralizing re-
sponses to MGRM8, while 4 out of 4 animals immunized with
MGRM8 alone failed to do the same. CRF250 neutralizing ac-
tivity in P5672 was trimer dependent, whereas all responses
elicited using CRF250 immunogen alone were gp120 specific,
suggesting a modulation of the neutralizing response to
CRF250 in the context of the SOSIP mixture. Animal P5672
also uniquely elicited nAbs to five heterologous tier 2 viruses,
and it is of interest to gain a better understanding of how this
was accomplished.
The range of trimer dependencies in C108- and WITO-immu-
nized animals is interesting given the dominant epitope targeted
was mapped to the V2 apex. This epitope is generally trimer
dependent for prototype bnAbs. While rare, some strains of
HIV, including C108, can bind to PG9 and PG16 bnAbs asmono-
meric gp120s (Figure S1C). This suggests it may be possible to232 Cell Reports 21, 222–235, October 3, 2017elicit nAbs to this epitope with a range of trimer dependencies
for some strains. Alternatively, neutralizing responsesmay target
a V2-apex epitope that does not completely overlap with proto-
type bnAbs and may not be trimer dependent.
We isolated neutralizing mAbs to evaluate whether they
possessed lineage properties that show promise for eventual af-
finity maturation into bnAbs. Like human V2-apex prototype
bnAbs, all neutralizing rabbit mAbs recognize the V2 basic region
of strand-C lysines (K169/K171) to some degree. Because
CDRL3s lengths are longer in the rabbit antibody repertoire
than in the human (Lavinder et al., 2014), contact through this
complementarity-determining region (CDR) is a distinct possibil-
ity. Encouragingly, we found that three out of six mAbs showed
dependence on glycans similar to human V2-apex bnAbs (An-
drabi et al., 2015), and some mAbs were able to tolerate glycans
introduced to fill the V2-apex glycan hole, even at position 130.
These features are promising for further affinity maturation to-
ward broad HIV neutralization.
In summary, this study describes reproducible vaccine-eli-
cited tier 2 autologous nAb responses directed toward an
epitope that overlaps that of prototype V2-apex-directed bnAbs
in an outbred animal model, and it provides a starting point from
which to test boosting strategies designed to broaden these re-
sponses to generate V2-apex bnAbs capable of protecting
against global HIV isolates.
EXPERIMENTAL PROCEDURES
Antibodies and Virus Envelopes
Mature, iP, and UCA antibody sequences used in this study are described in
Andrabi et al. (2015) and Doria-Rose et al. (2014). Virus envelopes from refer-
ence strains previously described (Seaman et al., 2010) were obtained from
NIH AIDS Research and Reference Reagent Program (ARRR). The sequence
ofMGRM_AG_002_8 (subtype AG) was obtained fromMonogramBiosciences
and cloned in to the pSVIII vector as described elsewhere (Helseth et al., 1990).
Amino acid point mutations in HIV envelopes were made using a QuikChange
site-directed mutagenesis kit (Stratagene) according to the manufacturer’s in-
structions. All mutations were verified by DNA sequence analysis (Eton
Bioscience).
Virus Production and Neutralization Assay
Single-round infectious HIV-1 Env pseudoviruses were made as described
previously (Seaman et al., 2010). Briefly, plasmids encoding Env were co-
transfected with an Env-deficient backbone plasmid (pSG3DENV) using Fu-
gene 6 (Promega). For kif-grown viruses, 25 mM kif was added to 293T cells
on the day of transfection. Cell media were harvested 48 hr post-transfection
and stored at 80C. Neutralization of pseudoviruses by IgG samples was
measured on TZM-bl target cells, as described previously (Seaman et al.,
2010). Neutralizing rabbit serum IgG or mAbs were reported as the antibody
concentration that resulted in 50% virus neutralization (IC50) in micrograms
IgG per milliliter after fitting the curve of log[antibody] versus percent neutral-
ization in Prism. For neutralization absorption assays, 0.1 mg/mL D368R
gp120 or SOSIP was incubated with 200 mg/mL IgG for 1 hr at 37C before
adding virus and proceeding as above.
Generation of iP-Binding Soluble Native Trimers
HIV-1 Env amino acid sequences (GenBank: JN944660 [C108.c03];
GenBank: EU13189 [CRF-T250-4]; GenBank: AY835451 [WITO.4130]; Gen-
Bank: MF510462 [MGRM-002-8]) were used to generate codon-optimized
SOSIP.664 gp140 genes (Geneart, Life Technologies) for expression of soluble
native trimers as described in Sanders et al. (2013). Tissue plasminogen acti-
vator (TPA) leader sequences were used and genes were cloned into phCMV
vectors (Genlantis) for transient transfection in 293F cells. Secreted trimers
were purified from cell supernatants after 5 days using PGT145 bnAb antibody
affinity columns as described previously (Pugach et al., 2015). D368R versions
of these proteins and sequence-matched gp120s were expressed in the same
way and purified usingGallanthus nivalis lectin (GNL) (Vector Labs). Affinity-pu-
rified proteins were purified by size exclusion chromatography using a Super-
dex 200 10-300 GL column (GE Healthcare) in PBS.
Trimer Characterization
N-glycan site occupancy of trimers was performed as described in Behrens
et al. (2016). Negative-stain EM, DSC, and BLI/Octet were performed as
described elsewhere (Guenaga et al., 2015).
Ethics Statement
This study was approved and carried out in accordance with protocols
provided to the Institutional Animal Care and Use Committee (IACUC) at The
Scripps Research Institute (TSRI; La Jolla, CA) under approval number
14-0002. The rabbits were kept, immunized, and bled at TSRI in compliance
with the Animal Welfare Act and other federal statutes and regulations relating
to animals and in adherence to the Guide for the Care and Use of Laboratory
Animals (National Research Council, 1996).
Immunization and Sampling
20 female 12-week-old New Zealand white rabbits were primed and boosted
with 50 mg protein and 100 U Iscomatrix in 600 mL PBS (300 mL IM injection into
each hind leg). Blood was drawn from the marginal ear vein into EDTA or un-
treated blood collection tubes. All procedures were performed in anesthetized
animals. EDTA plasmaswere diluted three timeswith PBS and PBMCs purified
on a Lymphoprep (STEMCELL Technology) density gradient. PBMCs were
cryopreserved in FBS plus 10% DMSO.
Purification of Polyclonal IgG from Serum
Clotted, filtered serum samples were mixed with protein A/G and incubated
overnight at 4Cwith agitation. Beads were washed with PBS and eluted using
0.1Mcitric acid (pH 3.0) and neutralizedwith 1MTris (pH 9.0). Purified IgGwas
buffer exchanged into PBS and stored at 200 mg/mL at 4C for neutralization
and ELISAs.
ELISA
SOSIP ELISA reagents were randomly biotinylated using a 2:1 molar ratio of
biotin reagent to trimer using the EZ-link-NHS-PEG4-Biotin kit (Thermo Fisher
Scientific, 21324) MaxiSorp plates (Thermo Fisher Scientific) were coated
overnight at 4C with 2 mg/mL gp120 protein or 2 mg/mL streptavidin (Thermo
Fisher Scientific). Plates were blocked for 1 hr with 3% BSA and washed three
times with 0.05% Tween 20-PBS (PBS-T) (pH 7.4). Streptavidin-coated plates
were incubated with randomly biotinylated SOSIPs in 1% BSA plus PBS-T for
2 hr and washed three times with PBS-T. Purified rabbit serum IgG or human
mAbs were added at a maximum concentration of 200 mg and 10 mg/mL,
respectively, serially diluted 1:6 in 1% BSA plus PBS-T, and incubated at
room temperature (RT) for 1 hr. Plates were washed three times with PBS-T.
Alkaline-phosphatase-conjugated goat anti-human or anti-rabbit IgG Fc sec-
ondary antibody (Jackson ImmunoResearch Laboratories) was diluted 1:500
in 1%BSAPBS-T and added to plates for 1 hr at RT. Plates were washed three
times with PBS-T and incubated with phosphatase (Sigma) for 60 min and the
absorbance at 405 nm recorded. The bnAb reactivity with biotinylated SOSIPs
proved that these reagents contained native epitopes. Direct coating of gp120
on plates showed similar results but better dynamic range than gp120 capture
using an anti-C5 antibody.
Rabbit Monoclonal nAbs
Fluorescence-activated cell sorting of cryopreserved PBMCs was performed
as described in McCoy et al. (2016). Briefly, IgM, IgG+, antigen-specific
B cells were sorted using randomly biotinylated (Thermo Fisher Scientific,
20217), PGT145-purified SOSIPs (sequence matched to the autologous
neutralizing activity in the animal from which the B cells were obtained) as
streptavidin-allophycocyanin-bound tetramers (Thermo Fisher Scientific,
SA1005). Single cells were sorted into 96-well plates for PCR amplification
of heavy and kappa chains using previously described primers and PCR con-ditions (McCoy et al., 2016). Rabbit antibody variable regions were cloned into
an expression plasmid adapted from the pFUSE-rIgG-Fc and pFUSE2-CLIg-
rK2 vectors (InvivoGen) under ampicillin selection.
Statistical Analysis
Correlations indata reported inFigures2andS2Cwereassessed inPrismusinga
two-tailed Spearman’s rank correlation coefficient. p values less than 0.05 were
considered significant. Heterologous tier 2 virus neutralization titration curves re-
ported in Figure 3C are the average percent neutralizations from three replicate
experiments with SDs reported as bars above and below the data points.
DATA AND SOFTWARE AVAILABILITY
The accession number for the envelope nucleotide sequence from called AG
HIV isolate MGRM_002_8 (obtained from Monogram and previously unpub-
lished) is GenBank: MF510462. The accession numbers for the monoclonal
rabbit antibody sequences are GenBank: MF510450 and MF510451
(3903-1); MF510452 and MF510453 (3903-2); MF510454 and MF510455
(3903-3); MF510456 and MF510457 (3907-1); MF510458 and MF510459
(3907-1); and MF510460 and MF510461 (3898-1)..
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